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Background
Congenital hyperinsulinism is a dysregulated insulin
secretion that results in persistent hypoglycemia. It is a
heterogenous condition but common to all is the inap-
propriately high insulin during hypoglycemia with
absence ketone bodies and reduced free fatty acids.
Case presentation
A baby boy with birth weight of 2.4kg at 35 weeks was
born via Caesarian section. The boy was allowed feeding
on demands, however he had the first onset of hypoglyce-
mia at 2 hours of life. His blood sugar ranged from low
reading to 2.5 mmol/L. The patient was treated with
boluses of intravenous dextrose D10% followed by main-
tenance dextrose with its increasing strength in order to
treat the refractory hypoglycemia. In addition to that
intravenous hydrocortisone and glucagon infusion were
started. The patient’s blood sugar could only be main-
tained > 3.0mmol/L after a glucose load of 30mg/kg/min
and a glucagon infusion of 50mcg/kg/hour. During hypo-
glycemia, the insulin level was 19.6 pmol/L (17.8-173.0)
and blood ketone was negative. Oral diazoxide was
started at 5.0mg/kg/day in divided doses combined with
chlorothiazide 7.0 mg/kg/day. Diazoxide was titrated up
to 20.0mg/kg/day as he had a poor response even after
1 week of the treatment. Apart from that oral nifidipine
2.5 mg/kg/day in divided doses was also started after a
few days with the combination therapy. Only after start-
ing octreotide infusion a good rise of blood sugar was
seen within 1 hour and the glucose load could be brought
down and the other drugs were off. The boy was dis-
charged with subcutaneous octreotide infusion at 2mcg/
hour via portable insulin pump.
Results
The boy is heterozygous for an ABCC8 nonsense muta-
tion, p.R934*. A second ABCC8 mutation has not been
found and sequencing of the KCNJ11 gene failed to
detect a change from the normal sequence. He has
inherited the mutation from his father; a focal lesion is
therefore possible. 18F-DOPA PET-CT scanning is
recommended and if a focal lesion is identified and sur-
gically resected, microsatellite analysis of the DNA can
be undertaken to confirm loss of heterozygosity.
Conclusion
KATP mutation is the commonest cause for diazoxide
resistant congenital hyperinsulinism.
Continuous subcutaneous octreotide infusion is a fea-
sible alternative to pancreatic surgery.
Written informed consent was obtained from the
patient’s parent or guardian for publication of this
abstract and any accompanying images. A copy of the
written consent is available for review by the Editor of
this journal.
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